On January 9, Aventis Behring Japan and UCB Japan have agreed that the latter will transfer to the former the promotion operations of “Sanlopor,” an immune globulin intravenous injection. This transfer will go into effect on April 1. Aventis Behring will assume consumer information service while Anventis Pharma will undertake the exporting and distributing of the product.
